NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...
NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...
nRx Pharmicals 股價上漲，此前該公司在最近完成的自殺性雙相情感障礙患者臨床試驗中宣佈，與護理比較標準相比，NRX-101 具有統計學上的顯著安全優勢...
NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar Depression and Plans to Seek Accelerated Approval of NRX-101.
nRx Pharmicals在最近完成的針對自殺性雙相抑鬱症患者的臨床試驗中宣佈，與護理比較標準相比，NRX-101 具有統計學上的顯著安全優勢，此後，該公司股價走高，並計劃尋求加速批准 NRX-101。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。